Rapid Dose Therapeutics and McMaster University's Incorporation of Loratadine-Cyclodextrin Complexes in Oral Thin Films for Rapid Drug Delivery
Rapid Dose Therapeutics, in collaboration with McMaster University, has published a groundbreaking study on incorporating loratadine-cyclodextrin complexes into Oral Thin Films (OTF) for rapid drug delivery. This method increases the solubility of loratadine, commonly known as Claritin, allowing it to be effectively loaded into RDT's QuickStrip delivery platform. The study, published in the Journal of Pharmaceutical Sciences, funded by the Natural Sciences and Engineering Research Council of Canada and RDT, highlights significant enhancements in drug solubility and delivery. This collaboration aims to improve patient outcomes by offering an efficient alternative drug delivery route.
- Successful incorporation of loratadine into Oral Thin Films increases drug solubility and delivery efficiency.
- Collaboration with McMaster University enhances RDT’s research and development capabilities.
- Publication in the Journal of Pharmaceutical Sciences adds scientific credibility.
- Funded by a Collaborative Research and Development grant, demonstrating strong financial support.
- Potential for improving patient outcomes by providing a new drug delivery method.
- No immediate financial impact or revenue increase mentioned.
- R&D and collaboration costs could potentially strain financial resources.
- Regulatory approval for new delivery methods could pose challenges and delays.
Burlington, Ontario--(Newsfile Corp. - May 22, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") trading on the Canadian Securities Exchange ("CSE") under the symbol DOSE in partnership with McMaster University ("McMaster") is pleased to announce the publication of the results of their collaborative research project titled "Incorporation of Loratadine-Cyclodextrin Complexes in Oral Thin Films ("OTF") for Rapid Drug Delivery" in the Journal of Pharmaceutical Sciences.
This research project enabled RDT to advance its formulation capabilities by successfully utilizing a method that increases the solubility of the commonly used drug loratadine, allowing it to be effectively loaded into the QuickStrip™ delivery platform. The described method can additionally improve the organoleptic properties of the films. Loratadine, sold under the brand name Claritin, among others, is an antihistamine commonly used to treat allergic rhinitis. It undergoes liver first pass metabolism and is a prime candidate for incorporation within an OTF.
The team found that by using specific types and ratios of cyclodextrins, loratadine complexes could be formed that led to great improvements in aqueous solubility and overall drug delivery performance. The publication can be viewed using the following DOI: https://doi.org/10.1016/j.xphs.2023.11.011
The project was funded via a Collaborative Research and Development grant awarded by the Natural Sciences and Engineering Research Council of Canada along with a matching funding contribution from RDT.
Mark Upsdell, CEO of RDT said "that through this research opportunity and partnering with McMaster University, this study has the potential to significantly enhance patient outcomes by providing an alternative route of delivery."
McMaster University research team lead Dr. Alex Adronov, PhD adds, "This proof-of-concept demonstration illustrates the potential utility of OTFs for the rapid and convenient delivery of numerous therapeutic agents."
This publication demonstrates RDT's ability to formulate and develop new products through both its internal scientific team and through its external collaborators.
About Rapid Dose Therapeutics Corp.
Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company's flagship product QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient. For more information about the Company, visit www.rapid-dose.com.
Contacts:
RDT Investor Contact:
Mark Upsdell, CEO
mupsdell@rapid-dose.com
416-477-1052
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:
Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend", "will", "could", "are planned to", "are expected to" or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip™ product delivery method, the generation of recurring revenues, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/210055
FAQ
What is the focus of the Rapid Dose Therapeutics and McMaster University collaboration?
How does the new method improve loratadine's effectiveness?
What is loratadine commonly used for?
What publication featured the study on loratadine-cyclodextrin complexes?
What is the potential impact of the new drug delivery method?
What funding supported the research project?
Did the study involve any external collaborations?
